Adipose type I interferon signalling protects against metabolic dysfunction

作者：Wieser Verena; Adolph Timon Erik; Grander Christoph; Grabherr Felix; Enrich Barbara; Moser Patrizia; Moschen Alexander Rupert; Kaser Susanne; Tilg Herbert^*

来源：Gut, 2018, 67(1): 157-165.

DOI：10.1136/gutjnl-2016-313155

Objective Low-grade chronic inflammation emerges as a potent driver of insulin resistance and glucose dysregulation in obesity and associated non-alcoholic fatty liver disease (NAFLD). The liver, subcutaneous fat and the immune system participate in disturbances of metabolism. Type I interferon (IFN) signalling initiated by innate and adaptive immunity modulates inflammatory responses consequent to infection. However, little is known about the role of type I IFN signalling in metabolic diseases and the development of NAFLD.
Design We determined the impact of type I IFN signalling by tissue-specific deletion of interferon (alpha and beta) receptor 1 (Ifnar1) in hepatocytes (Ifnar1(Delta hep)), adipocytes (Ifnar1(Delta at)), intestinal epithelial cells (Ifnar1(Delta IEC)) or myelocytes (Ifnar1(Delta myel)) on glucose metabolism, obesity and hepatic disease in mice exposed to a high-fat or methionine-choline-deficient (MCD) diet. Furthermore, we investigated the expression of type I IFN-regulated genes in patients with obesity undergoing laparoscopic adjustable gastric banding (LAGB).
Results Long chain fatty acids induce type I IFN responses in murine hepatocytes and macrophages and exposure to a high-fat diet elicited type I IFN-regulated gene expression in the liver of wild-type mice. Hepatocyte-specific, but not adipose tissue-specific deletion of Ifnar1 worsened steatosis and inflammation induced by the MCD diet. In contrast, adipose-specific, but not hepatocyte-specific deletion of Ifnar1 deteriorated metabolic dysregulation induced by a highfat diet, indicated by increased weight gain, insulin resistance and an impaired glucose tolerance. Abrogated type I IFN signalling in myeloid or intestinal epithelial cells did not modulate susceptibility to metabolic or hepatic disease. Improved metabolic control in patients with obesity after LAGB was associated with increased expression of type I IFN-regulated genes in subcutaneous adipose tissue and liver.
Conclusions Our study implicates a role for adipose and hepatocyte type I IFN signalling in diet-induced metabolic dysregulation and hepatic disease. Further studies on type I IFN signalling in metabolic diseases are warranted.

• 出版日期2018-1